BTN3A1 and prostate neoplasm: Here, we show that these stress-associated ligands, in addition to BTN3A1, are expressed by bone metastatic prostate tumors (Fig. 1), and their expression in biopsies may help select patients who will respond best to γδ CAR-T cell therapies in prospective clinical trials.